Prospektive, multizentrische Studie zur Bedeutung der O-(2-[¹⁸F]Fluoroethyl)-L-Tyrosin-Positronen-Emissions-Tomografie (FET-PET) in der Verlaufsbeurteilung von Hirntumoren im Kindes- und Jugendalter (FET PET 2010)

Zusammenfassung

Wir beschreiben das Studienprotokoll einer prospektiven, multizentrischen Studie zum Stellenwert der ¹⁸F-FET-PET in der Nachsorge von Hirntumoren im Kindes- und Jugendalter. Das Hauptziel dieser Studie ist die Evaluierung der Wertigkeit der ¹⁸F-FET-PET im Vergleich zur MRT zum Resttumor-/Rezidivnachweis nach einer „first line“-Therapie bei Kindern und Jugendlichen mit ZNS-Tumoren. Insgesamt 160 pädiatrische Patienten sollen eingeschlossen werden. Die Gesamtdauer der Studie wird 3 Jahre betragen.

Summary

We present a study concept of a prospective, multicentre trial on the value of ¹⁸F-FET PET in the post-therapeutic evaluation of childhood brain tumors (FET PET 2010). The main objective of this study is to evaluate the performance of ¹⁸F-FET PET in comparison to the MRI in differentiating residual tumor/recurrence from therapy-related changes in pediatric brain tumors after first line therapy. 160 patients will be recruited in this German multicenter study. Duration of study will be 3 years for all patients.

Schlüsselwörter

F18-FET - Positronen-Emissions-Tomografie - Hirntumoren

Key words

F18-FET - Positron-Emission-Tomography - brain tumors

*

^* Die Autoren haben gleichermaßen zu dieser Studie beigetragen.

• Literatur

• 1 EMEA. GUIDELINE ON CLINICAL EVALUATION OF DIAGNOSTIC AGENTS. European Medicines Agency. , Doc. Ref. CPMP/EWP/1119/98/Rev 1 2008.
• 2 Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005; 128: 678-687
• 3 Rachinger W, Goetz C, Popperl G et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine vs. magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005; 57: 505-511 discussion 505–511
• 4 Nataf V, Kerrou K, Balogova S et al. [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bull 2010; 97: 495-506
• 5 Lau EW, Drummond KJ, Ware RE et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 2009; 17: 43-49
• 6 Pauleit D, Stoffels G, Bachofner A et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 2009; 36: 779-787
• 7 Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002; 12: 615-626
• 8 Weber WA, Wester HJ, Grosu AL et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27: 542-549
• 9 Moulin-Romsee G, D′Hondt E, de Groot T et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?. Eur J Nucl Med Mol Imaging 2007; 34: 2082-2087
• 10 Messing-Junger AM, Floeth FW, Pauleit D et al. Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas. Childs Nerv Syst 2002; 18: 445-449
• 11 Weckesser M, Langen KJ, Rickert CH et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005; 32: 422-429
• 12 Benouaich-Amiel A, Lubrano V, Tafani M et al. Evaluation of O-(2-[18F]-Fluoroethyl)-L-Tyrosine in the Diagnosis of Glioblastoma. Arch 2010; 67: 370-372
• 13 Popperl G, Gotz C, Rachinger W et al. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004; 31: 1464-1470
• 14 Mehrkens JH, Popperl G, Rachinger W et al. The positive predictive value of O-(2-[(18)F]fluoroethyl)-L: -tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008; 23: 23
• 15 Popperl G, Kreth FW, Herms J et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med 2006; 47: 393-403
• 16 Popperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007; 34: 1933-1942
• 17 Plotkin M, Blechschmidt C, Auf G et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur 2010; 20: 2496-2502
• 18 Stockhammer F, Misch M, Horn P et al. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien) 2009; 151: 1377-1383
• 19 Plotkin M, Gneveckow U, Meier-Hauff K et al. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperthermia 2006; 22: 319-325
• 20 Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother 2010; 96: 325-327
• 21 Piroth MD, Pinkawa M, Holy R et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme – a dosimetric comparison. Radiat Oncol 2009; 4: 57
• 22 Rickhey M, Koelbl O, Eilles C et al. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol 2008; 184: 536-542
• 23 Popperl G, Goldbrunner R, Gildehaus FJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-1025
• 24 Popperl G, Gotz C, Rachinger W et al. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006; 33: 792-800
• 25 Stockhammer F, Misch M, Koch A et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J 2010; 100: 407-415
• 26 Piroth MD, Pinkawa M, Holy R et al. Prognostic Value of Early [(18)F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys 2010; 2010: 18
• 27 Thiele F, Ehmer J, Piroth MD et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009; 54: 5525-5539
• 28 Pauleit D, Stoffels G, Schaden W et al. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. J Nucl Med 2005; 46: 411-416
• 29 Floeth FW, Pauleit D, Wittsack HJ et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18 F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005; 102: 318-327
• 30 Floeth FW, Pauleit D, Sabel M et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007; 48: 519-527